AUTL: financial statements from SEC — TradeAlmanac

AUTL

Autolus Therapeutics plc: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Mar 31, 2026	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Sep 30, 2024	Jun 30, 2024
Revenue	26m	21m	21m	9m	0	0
Cost of revenue	25m	29m	24m	18m	0	0
Research and development	21m	28m	27m	27m	40m	37m
Selling, general and administrative	40m	36m	30m	30m	27m	22m
Operating income	−60m	−72m	−61m	−65m	−68m	−59m
Pre-tax income	−71m	−79m	−48m	−68m	−82m	−58m
Income tax	863,000	532,000	397,000	2m	22,000	51,000
Net income	−72m	−79m	−48m	−70m	−82m	−58m
Earnings per share	−0.27	−0.30	−0.18	−0.26	−0.31	−0.22
Earnings per share, diluted	−0.27	−0.30	−0.18	−0.26	−0.31	−0.22
Weighted average shares	266m	266m	266m	266m	266m	266m
Weighted average shares, diluted	266m	266m	266m	266m	266m	266m

Balance sheet

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024
Cash and equivalents	131m	104m	86m	124m	96m	227m	657m	706m
Receivables	28m	24m

Cash flow

Metric	Mar 31, 2026	Mar 31, 2025
Operating cash flow	−65m	−76m
Depreciation and amortisation	2m	2m
Capital expenditure	3m	8m
Investing cash flow	96m	−60m
Financing cash flow	−2m	0

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)